7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation

Routine and Specialized Coagulation Testing & Mixing Study Interpretation

The diagnostic hemostasis laboratory operates under stringent pre-analytical, analytical, and post-analytical quality control standards. Because in vitro coagulation assays depend on precise stoichiometric balances of calcium ions, phospholipids, and active proteases, pre-analytical collection errors represent the single largest cause of spurious laboratory results and clinical misinterpretation.

                               [ PRE-ANALYTICAL WORKFLOW ]

  1. Light-Blue Top Collection (3.2% Sodium Citrate) ──► Strict 9:1 Blood:Anticoagulant Ratio
                                     │
                                     ▼
  2. Check Hematocrit: If Hct > 55% ──► Adjust Citrate via C = 0.00185 × (100 - Hct) × Vblood
                                     │
                                     ▼
  3. Centrifugation (1500g × 15 min) ──► Platelet-Poor Plasma (PPP < 10,000/μL)
                                     │
         ┌───────────────────────────┴───────────────────────────┐
         ▼                                                       ▼
  [ ROUTINE SCREENING ]                                   [ SPECIALIZED TESTING ]
  - PT / INR (Extrinsic / Common)                         - 1:1 Mixing Studies (Immediate vs 2h Incubation)
  - aPTT (Intrinsic / Common)                             - dRVVT Screen & Confirm (Lupus Anticoagulant)
  - Thrombin Time & Reptilase Time                        - Bethesda Assay (Factor Inhibitor Titers)
  - Clauss Functional Fibrinogen                          - Single Factor Activity Assays

---

Specimen Collection & Pre-Analytical Variables

1. Anticoagulant Concentration and Ratio

• Standard Formulation: The CLSI (Clinical and Laboratory Standards Institute) standard anticoagulant is 3.2% (0.109 M) buffered sodium citrate in a light blue-top tube.
• Blood-to-Anticoagulant Ratio: Exactly 9 parts whole blood to 1 part sodium citrate (yielding a $9:1$ volumetric ratio, or $10%$ anticoagulant by total volume). Citrate functions by chelating ionized calcium ($Ca^{2+}$), arresting both the intrinsic and extrinsic cascades.
• Underfilled Tubes (<90% Fill): If an evacuated tube is underfilled, the relative volume of liquid citrate is excessive compared to the diminished plasma volume. The excess uncomplexed citrate binds reagent calcium added during the automated testing phase, leading to falsely prolonged PT and aPTT results.

2. High Hematocrit Adjustment Formula

In polycythemic patients (e.g., polycythemia vera, cyanotic congenital heart disease, severe neonatal erythrocytosis) whose Hematocrit exceeds 55%, the plasma volume per unit of whole blood is markedly decreased. The standard volume of sodium citrate provides an excess of anticoagulant relative to the reduced plasma fraction, causing spurious prolongation of clotting times.

The volume of 3.2% sodium citrate remaining in the tube must be reduced prior to collection according to the CLSI formula:

$C = 0.00185 \times (100 - \text{Hct}) \times V_{\text{blood}}$

Where:

• $C$ = Volume of 3.2% sodium citrate remaining in the tube (in $\text{mL}$).
• $\text{Hct}$ = Patient's hematocrit percentage (e.g., $65%$ entered as $65$).
• $V_{\text{blood}}$ = Target volume of whole blood to be drawn into the tube (in $\text{mL}$).

3. Order of Draw & Butterfly Dead-Space Clearance

• To prevent cross-contamination by additive activators (such as spray-coated clot activators in serum tubes or $K_2\text{EDTA}$ in purple tubes), the light blue sodium citrate tube must be drawn before other additive tubes.
• When using a winged blood collection set (butterfly needle), an initial non-additive or discard citrate tube must be drawn first to clear the air from the plastic tubing. Failure to prime the tubing leads to an underfilled blue-top tube and spurious test prolongation.

4. Centrifugation & Platelet-Poor Plasma (PPP)

• Definition: Platelet-Poor Plasma (PPP) is plasma containing a residual platelet count of $<10,000/\mu\text{L}$ ($<10 \times 10^9/\text{L}$).
• Preparation: Centrifugation of un-hemolyzed citrated whole blood at $1,500\text{ to }2,000\times g$ for 15 minutes at room temperature ($18\text{--}25^\circ\text{C}$).
• Why PPP is Essential: Residual platelets in plasma disrupt specialized testing:
  • During freeze-thaw cycles for batched or frozen testing, platelets lyse and discharge Platelet Factor 4 (PF4), which neutralizes unfractionated and low-molecular-weight heparin.
  • Platelet membrane fragments expose procoagulant phosphatidylserine, which neutralizes anti-phospholipid antibodies, causing false-negative Lupus Anticoagulant (LA) assays.

5. Interference Management: Optical vs. Mechanical Clot Detection

• Photo-Optical Clot Detection: Measures changes in optical density (light transmission or absorbance) as fibrin monomers polymerize into an opaque gel. Severely affected by in vitro hemolysis, gross lipemia, and marked icterus (bilirubinemia), which produce baseline optical baseline drift or premature optical cutoffs.
• Electromechanical / Magnetic Steel Ball Clot Detection: Detects the physical formation of a fibrin strand by measuring the disruption of an oscillating magnetic steel ball or electrical circuit impedance. Completely immune to optical interferences from hemolysis, lipemia, and hyperbilirubinemia.

---

Routine Screening Coagulation Assays

The International Normalized Ratio (INR)

Because commercial thromboplastin reagents have widely varying sensitivities to factor deficiencies, raw PT seconds cannot be compared across different laboratories. The International Normalized Ratio (INR) standardizes the PT for monitoring Vitamin K Antagonist (Warfarin) therapy:

$\text{INR} = \left( \frac{\text{Patient PT}}{\text{Mean Normal PT}} \right)^{\text{ISI}}$

Where:

• Mean Normal PT (MNPT): Geometric mean PT of at least 20–30 healthy reference donors established by each laboratory.
• International Sensitivity Index (ISI): Calibration factor assigned by the manufacturer against the WHO International Reference Thromboplastin. Highly sensitive reagents have an $\text{ISI} \approx 1.0$, minimizing mathematical magnification of errors.
• Therapeutic Targets: $\text{INR } 2.0\text{--}3.0$ for standard venous thromboembolism (DVT/PE), atrial fibrillation, and bioprosthetic valves; $\text{INR } 2.5\text{--}3.5$ for mechanical prosthetic mitral valves.

Dissecting Heparin Contamination: TT vs. Reptilase Time

                               [ TT vs REPTILASE ALGORITHM ]

                                  Prolonged Thrombin Time (TT)
                                               │
                                               ▼
                                    Perform Reptilase Time
                                               │
                       ┌───────────────────────┴───────────────────────┐
                       ▼                                               ▼
            REPTILASE TIME NORMAL                           REPTILASE TIME PROLONGED
          ─────────────────────────                       ────────────────────────────
          • Unfractionated Heparin                        • Dysfibrinogenemia
          • Direct Thrombin Inhibitors                    • Hypofibrinogenemia (<100 mg/dL)
            (Dabigatran, Argatroban)                      • Severe Elevation of FDPs / D-Dimer

---

Mixing Studies (1:1 Plasma Mixing Protocol)

When a patient presents with an unexplained prolonged PT and/or aPTT in the absence of therapeutic anticoagulation, a 1:1 mixing study is the mandatory algorithmic reflex test performed to differentiate a factor deficiency from a circulating inhibitor.

                                 [ 1:1 MIXING STUDY PROTOCOL ]

                          Patient Plasma + Normal Pooled Plasma (1:1 Ratio)
                                               │
                                               ▼
                                   Perform Immediate aPTT (Time 0)
                                               │
                      ┌────────────────────────┴────────────────────────┐
                      ▼                                                 ▼
              IMMEDIATE CORRECTION                            FAILS TO CORRECT
            (Returns to normal range)                     (Remains significantly prolonged)
                      │                                                 │
                      ▼                                                 ▼
         Incubate 1:1 Mix at 37°C for 2h                   IMMEDIATE-ACTING INHIBITOR
                      │                                    - Lupus Anticoagulant (LAC)
         ┌────────────┴────────────┐                       - Heparin / DOAC
         ▼                         ▼                       - Specific Rapid Inhibitor (rare)
     CORRECTION                PROLONGATION
     PERSISTS               (Loss of correction)
         │                         │
         ▼                         ▼
  FACTOR DEFICIENCY       TIME- & TEMP-DEPENDENT
  (e.g., FVIII, FIX,        FACTOR INHIBITOR
   FXI deficiency)        (Factor VIII Autoantibody)

Step-by-Step Diagnostic Interpretation

1. Preparation: Equal volumes ($1:1$) of patient plasma and Normal Pooled Plasma (NPP) (which contains $\sim 100%$ activity of all coagulation factors) are combined. A control mixture of NPP and patient plasma incubated separately is prepared in parallel.
2. Immediate 1:1 Mix Test (Time 0):
   • Full Correction: Clotting time normalizes to within the reference range (or within 10% of NPP). Because a factor level of only $30\text{--}50%$ is required to generate a completely normal PT or aPTT, the 1:1 mixture supplies at least $50%$ of every factor, fully correcting a true single or multiple factor deficiency.
   • Failure to Correct: The clotting time remains prolonged. Indicates the presence of an immediate-acting circulating inhibitor that neutralizes the reagents or clotting factors present in the donor pool (e.g., Lupus Anticoagulant, therapeutic Heparin, Direct FXa/FIIa inhibitors).
3. 2-Hour Incubation at $37^\circ\text{C}$ (Time- and Temperature-Dependence):
   • If the immediate mix corrects, the 1:1 mixture (along with separate incubated aliquots of patient plasma and NPP) is incubated at $37^\circ\text{C}$ for 2 hours.
   • Persistent Correction: Clotting time remains normal. Confirms a Factor Deficiency (e.g., Hemophilia A, B, C, or multiple factor deficiencies). Proceed to single-factor assays.
   • Loss of Correction / Progressive Prolongation: The incubated 1:1 mix prolongs significantly (typically $>3\text{--}5$ seconds longer than the incubated control pool). This time- and temperature-dependent kinetics is pathognomonic for a specific Factor VIII Autoantibody (Acquired Hemophilia A).

Mathematical Confirmation: Rosner Index of Circulating Anticoagulant (ICA)

To standardize the determination of correction versus non-correction and eliminate subjective cutoffs, laboratories apply the Rosner Index (ICA):

$\text{ICA (\%)} = \left[ \frac{\text{aPTT}_{1:1\text{ Mix}} - \text{aPTT}_{\text{NPP}}}{\text{aPTT}_{\text{Patient}}} \right] \times 100$

• $\text{ICA} < 11%$: Indicates Correction (consistent with Coagulation Factor Deficiency).
• $\text{ICA} > 15%$: Indicates No Correction / Presence of an Inhibitor (Lupus Anticoagulant or specific factor antibody).
• $\text{ICA } 11\text{--}15%$: Indeterminate / Borderline zone requiring further confirmatory testing.

---

Lupus Anticoagulant (LA) vs. Specific Factor Inhibitor Confirmation

                                  [ INHIBITOR DIFFERENTIATION ]

           CRITERIA                         LUPUS ANTICOAGULANT             FACTOR VIII AUTOANTIBODY
  ─────────────────────────────────────────────────────────────────────────────────────────────────
  In Vivo Clinical Risk            THROMBOSIS (Venous & Arterial)       SEVERE HEMORRHAGE (Soft tissue/skin)
  Immediate 1:1 Mix                Fails to correct (Immediate)         Corrects immediately
  2-Hour Incubated 1:1 Mix         No significant change                Prolongs markedly (Time/temp dependent)
  dRVVT Screen / Confirm Ratio     ≥ 1.20 (Phospholipid dependent)      Normal (<1.20, Non-phospholipid)
  Specific Factor Assays           Apparent multi-factor reduction      True isolated FVIII reduction
  Bethesda Titration Assay         Negative (<0.5 BU)                   Positive (Quantifiable Bethesda Units)

1. Dilute Russell Viper Venom Time (dRVVT)

• Principle: The venom of Daboia russelii directly activates Factor X in the common pathway in the presence of calcium and phospholipids, completely bypassing the contact factors, Factor XII, Factor XI, Factor IX, and Factor VIII.
• dRVVT Screen (Low Phospholipid): Employs a rate-limiting, dilute phospholipid concentration. In the presence of antiphospholipid antibodies (Lupus Anticoagulant), the antibodies bind the limited phospholipids, causing a markedly prolonged clotting time.
• dRVVT Confirm (High Phospholipid): Employs an excess concentration of bilayer phospholipids. The abundant phospholipids overwhelm and neutralize the antiphospholipid antibodies, restoring the clotting time to normal (shortening significantly).
• Normalized Ratio Calculation:

$\text{dRVVT Normalized Ratio} = \frac{\left( \frac{\text{Patient Screen PT}}{\text{Mean Normal Screen PT}} \right)}{\left( \frac{\text{Patient Confirm PT}}{\text{Mean Normal Confirm PT}} \right)}$

• Interpretation: A normalized ratio $\ge 1.20$ confirms the presence of a phospholipid-dependent Lupus Anticoagulant.

2. Bethesda Assay (Nijmegen Modification)

• Clinical Utility: Quantifies the precise titer of neutralizing factor-specific alloantibodies (in congenital hemophiliacs treated with factor concentrates) or autoantibodies (in acquired hemophilia A).
• Methodology: Serial dilutions of heat-inactivated patient plasma are mixed 1:1 with buffered normal pooled plasma (containing $100%$ FVIII) and incubated at $37^\circ\text{C}$ for 2 hours. Residual Factor VIII activity is measured against an incubated reference control.
• Definition of a Bethesda Unit (BU):
  • 1 Bethesda Unit (1 BU) is defined as the amount of specific inhibitor in $1\text{ mL}$ of patient plasma that will neutralize $50%$ of the Factor VIII activity in $1\text{ mL}$ of normal pooled plasma after a 2-hour incubation at $37^\circ\text{C}$.
  • Low-Responder Inhibitors: $<5\text{ BU}$ (may be overcome with high-dose factor replacement).
  • High-Responder Inhibitors: $\ge 5\text{ BU}$ (requires bypassing agents like activated prothrombin complex concentrate [FEIBA], recombinant Factor VIIa [NovoSeven], or emicizumab).